JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264948

Human UBE2O knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

UBE2O KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 8 and 2 bp deletion in exon 8. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

E2 230K, EC=6.3.2.19, FLJ12878, KIAA1734, Likely Ortholog of Mouse Ubiquitin Conjugating Enzyme, RP23 193A16.5, UBE2O_HUMAN, Ubiquitin carrier protein O, Ubiquitin-conjugating enzyme E2 O, Ubiquitin-conjugating enzyme E2 of 230 kDa, Ubiquitin-conjugating enzyme E2-230K, Ubiquitin-protein ligase O

3 Images
Sanger Sequencing - Human UBE2O knockout HeLa cell line (AB264948)
  • Sanger seq

Lab

Sanger Sequencing - Human UBE2O knockout HeLa cell line (AB264948)

Sequencing chromatogram displaying sequence edit in exon 8

Sanger Sequencing - Human UBE2O knockout HeLa cell line (AB264948)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2O knockout HeLa cell line (AB264948)

Allele-1 : 2 bp deletion in exon 8.

Sanger Sequencing - Human UBE2O knockout HeLa cell line (AB264948)
  • Sanger seq

Unknown

Sanger Sequencing - Human UBE2O knockout HeLa cell line (AB264948)

Allele-2 : 1 bp insertion in exon 8.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 8 and 2 bp deletion in exon 8

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264948-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264948-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264948 Human UBE2O knockout HeLa cell line", "number":"AB264948-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264948-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264948-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264948 Human UBE2O knockout HeLa cell line", "number":"AB264948-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264948-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264948 Human UBE2O knockout HeLa cell line", "number":"AB264948-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264948-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264948 Human UBE2O knockout HeLa cell line", "number":"AB264948-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
UBE2O
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

UBE2O also known as E2-230K or E2 ubiquitin-conjugating enzyme O is a protein that functions as an E2 ubiquitin-conjugating enzyme. It has a molecular mass of approximately 141 kDa. UBE2O plays a role in transferring ubiquitin to substrate proteins marking them for degradation via the proteasome. This process is important for protein quality control and cellular homeostasis. UBE2O is expressed in various tissues including the brain liver and skeletal muscle indicating its broad physiological significance.
Biological function summary

UBE2O facilitates the regulation of protein turnover by mediating ubiquitination without the need for an E3 ligase. It acts both as an E2 and has E3 activity making it a versatile factor in the ubiquitin-proteasome system. UBE2O also participates in muscle differentiation by targeting specific muscle regulatory factors for ubiquitination. Understanding its function provides insights into the control of muscle mass and function highlighting its contribution to cellular growth and adaptation.

Pathways

UBE2O interacts with essential biological mechanisms notably the ubiquitin-proteasome pathway involved in protein degradation. It also participates in cell cycle regulation by targeting certain cyclin proteins for degradation ensuring proper cell cycle progression. UBE2O works in conjunction with other proteins like ANAPC10 and CDC20 which are important in cell cycle control and proteostasis.

UBE2O has associations with conditions such as myopathies and certain cancers. In muscle disorders UBE2O dysregulation can lead to abnormal protein accumulation affecting muscle function. In oncology UBE2O interacts with proteins like P53 which is important in cell cycle regulation and apoptosis. Its role in these disorders underlines its importance as a potential therapeutic target for intervention in these diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com